JAK Inhibitors in Difficult Still’s Disease

Save

A small retrospective study suggests that patients with difficult to treat adult-onset Still's disease (AOSD) or sytemic juvenile idiopathic arthritis (sJIA) may respond well to JAK inhibitor (JAKi) agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN.

Read Article

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Save

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

Read Article

The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/vTM4x53n7k https://t.co/aQcuMury2k

Belimumab (Benlysta) has been FDA approved for use in pediatric patients with active lupus nephritis who are receiving standard lupus therapy. The approval in kids is for the IV formulation only; SC belimumab is for SLE and LN in adults https://t.co/TKyNDwIUQH https://t.co/6VaMOMfwYi

Not Still’s – Now What?

Save

Your patient doesn't meet criteria for Still’s disease (AOSD or sJIA), now what should you do or consider?

What you do or consider next can be addressed according to the stage of current disease: A) Hospitalized Febrile Disease, or B) Outpatient “Still’s” Disease.

Read Article

TNR: Still's Now Journal Club - Pivotal Trials in SJIA & AOSD Approved Meds This week's Stills disease Journal Club features expert panelists Drs. Olga Petryna, Daniel Lovell, Hermine Brunner and Jack Cush.https://t.co/2TCtByJg4Q https://t.co/arqQUQJNNC

Rheumatic Causes for Fever of Unknown Origin

Save

Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.

Read Article

Early, Aggressive and Seropositive (7.22.2022)

Save

Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.

Read Article

Myths & Misconceptions with Febrile Disorders Dr. Rachel Tate ( @uptotate) weighs on the myths and misconceptions with Still's disease and autoinflammatory disorders. https://t.co/z0KHbxnLjJ https://t.co/ymsXYDP5Zs

Fever Pitch (7.15.2022)

Save

Dr. Jack Cush reviews the new studies and drug approvals and new insights into febrile disorders from the past week on RheumNow.com

Read Article

Still’s Disease FAQs

Save

What is the classic 'triad' of Still's disease? Does it affect males and females equally? What are typical lab findings? Which drugs are effective at treating Still's, and as importantly, which ones are not? What about complications? Read on for these and other FAQs regarding Still's disease.

Read Article

MRP8/14 as a Biomarker in Systemic Juvenile Idiopathic Arthritis

Save

A large cohort study of children with febrile disorders has demonstrated the diagnostic utility of Myeloid-related protein 8/14 (MRP8/14) in diagnosing systemic JIA patients (SJIA) in clinical practice.

Read Article

Guidelines for MAS complicating Systemic JIA: Dx is based on: - Fever in sJIA with ^ ferritin > 684, plus - Any 2 of these: elevated PLTs, AST, Triglycerides or low Fibrinogenhttps://t.co/aIEvxRYZca https://t.co/DYpLHxRCzI

ICYMI: 2021 Rheumatology Year in Review

Save

For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article

Adults with JIA: It ain’t all child’s playhttps://t.co/z3xDjKH2ru https://t.co/9DDGYdpMSr

EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/6pWc6nEUd9 https://t.co/gGGyzEEh0u

What Worries You, Masters You (7.1.2022)

Save

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.

Read Article

New Updated GRAPPA Psoriatic Arthritis Recommendations

Save

The GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) treatment recommendations have been updated and the 2021 evidence-based guidance is rich in treatment recommendations based on the key disease "domains" - peripheral arthritis, axial disease, enthesitis, dactylitis, skin and nail psoriasis; with new PsA related domains uveitis and inflammatory bowel disease.

Read Article

What Happened to Kawasaki Disease During COVID-19?

Save

During the COVID-19 pandemic, a new COVID-related syndrome in children, the "Multisystem inflammatory syndrome in children" (MIS), was described as being similar to but distinctly different than childhood Kawasaki's disease (KD). A new epidemiologic report shows that while MIS-C cases rose, KD cases fell and remained low during the period of masking and school closure.

Read Article

Two Week Twitter (6.17.2022)

Save

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.

Read Article